Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 4/20 | 0.75 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.75 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.75 |
| ▸ | POLB | P06746 | 1/20 | 0.75 |
| ▸ | TYR | P14679 | 1/20 | 0.75 |
| ▸ | HSPA5 | P11021 | 1/20 | 0.55 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.55 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.53 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.53 |
| ▸ | CA1 | P00915 | 2/20 | 0.52 |
| ▸ | TSHR | P16473 | 3/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | TNFRSF1A | P19438 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Butylated Hydroxytoluene SCHEMBL530460 | 0.90 | CA2 (0.72) | CA2SMN1; SMN2ALDH1A1POLBTYR | |
| Butylated Hydroxytoluene SCHEMBL4170581 | 0.89 | SMN1; SMN2 (0.95) | CA2SMN1; SMN2ALDH1A1POLBTYR | |
| Butylated Hydroxytoluene SCHEMBL1446620 | 0.88 | CA2 (0.75) | CA2SMN1; SMN2ALDH1A1POLBTYR | |
| Butylated Hydroxytoluene SCHEMBL6436436 | 0.87 | SMN1; SMN2 (0.90) | CA2SMN1; SMN2ALDH1A1POLBTYR | |
| Butylated Hydroxytoluene SCHEMBL3950 | 0.87 | SMN1; SMN2 (1.00) | CA2SMN1; SMN2ALDH1A1POLBTYR | |
| Butylated Hydroxytoluene SCHEMBL453824 | 0.87 | SMN1; SMN2 (1.00) | CA2SMN1; SMN2ALDH1A1POLBTYR | |
| Toluene SCHEMBL27737615 | 0.86 | CA2 (0.55) | CA2SMN1; SMN2ALDH1A1POLBTYR | |
| Butylated Hydroxytoluene SCHEMBL7590469 | 0.86 | ALDH1A1 (0.72) | CA2SMN1; SMN2ALDH1A1POLBTYR | |
| Butylated Hydroxytoluene SCHEMBL3687285 | 0.85 | CA2 (0.78) | CA2SMN1; SMN2ALDH1A1POLBTYR | |
| Butylated Hydroxytoluene SCHEMBL9394538 | 0.85 | CA2 (0.78) | CA2SMN1; SMN2ALDH1A1POLBTYR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115029407-A | Preparation method of chilli seed antioxidant | 四川农业大学 | 2022-09-09 | — | — | CN | disclosed |
| CN-110734508-B | Method for disassembling natural rubber | 中国热带农业科学院农产品加工研究所 | 2020-09-04 | — | — | CN | disclosed |
| CN-110734508-A | Method for disassembling natural rubbers | 中国热带农业科学院农产品加工研究所 | 2020-01-31 | — | — | CN | disclosed |
| US-20100003711-A1 | Methods to identify therapeutic agents | THE SCRIPPS RESEARCH INSTITUTE (US) | 2010-01-07 | — | — | US | disclosed |
| US-20090275064-A1 | Methods to identify therapeutic agents | THE SCRIPPS RESEARCH INSTITUTE (US) | 2009-11-05 | — | — | US | disclosed |
| US-20070059242-A1 | METHODS TO IDENTIFY THERAPEUTIC AGENTS | SCRIPPS RESEARCH INSTITUTE, THE | 2007-03-15 | — | — | US | disclosed |
| US-20060217359-A1 | Therapeutic procedures | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2006-09-28 | — | — | US | disclosed |
| US-20060210554-A1 | Detection of cholesterol ozonation products | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2006-09-21 | — | — | US | disclosed |
| EP-1670812-A2 | OZONATION PRODUCTS OF CHOLESTEROL FOR THE TREATMENT AND PREVENTION OF ATHEROSCLEROSIS AND/OR CARDIOVASCULAR DISEASES | The Scripps Research Institute (US) | 2006-06-21 | — | — | EP | disclosed |
| EP-1668026-A1 | DETECTION OF CHOLESTEROL OZONATION PRODUCTS | The Scripps Research Institute (US) | 2006-06-14 | — | — | EP | disclosed |
| US-20050085557-A1 | Oxidation of cholesterol in atherosclerosis plaque; cytotoxic | SCRIPPS RESEARCH INSTITUTE, THE | 2005-04-21 | — | — | US | disclosed |
| US-20050085556-A1 | Detection of cholesterol ozonation products | SCRIPPS RESEARCH INSTITUTE, THE | 2005-04-21 | — | — | US | disclosed |
| WO-2005023830-A2 | OZONATION PRODUCTS OF CHOLESTEROL FOR THE TREATMENT AND PREVENTION OF ATHEROSCLEROSIS AND/OR CARDIOVASCULAR DISEASES | THE SCRIPPS RESEARCH INSTITUTE (US) | 2005-03-17 | — | — | WO | disclosed |
| WO-2005023831-A1 | DETECTION OF CHOLESTEROL OZONATION PRODUCTS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2005-03-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070059242-A1 | METHODS TO IDENTIFY THERAPEUTIC AGENTS | MSR1, SCARB1, LDLR | CA2 4150/4885SMN1; SMN2 4510/4885ALDH1A1 1131/4885 |
| US-20050085556-A1 | Detection of cholesterol ozonation products | APOB, CETP, PCSK9 | CA2 2003/4885SMN1; SMN2 4834/4885ALDH1A1 2555/4885 |
| US-20050085557-A1 | Oxidation of cholesterol in atherosclerosis plaque; cytotoxic | APOB, LDLR, CETP | CA2 3181/4885SMN1; SMN2 4704/4885ALDH1A1 2866/4885 |
| US-20060217359-A1 | Therapeutic procedures | APOB, LIPA, CETP | CA2 1626/4885SMN1; SMN2 4498/4885ALDH1A1 2247/4885 |
| US-20090275064-A1 | Methods to identify therapeutic agents | MSR1, SCARB1, LDLR | CA2 3944/4885SMN1; SMN2 4549/4885ALDH1A1 1174/4885 |
| US-20060210554-A1 | Detection of cholesterol ozonation products | APOB, CETP, PCSK9 | CA2 2003/4885SMN1; SMN2 4834/4885ALDH1A1 2555/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.